- In a March 29, 2018 press release, the Food and Drug Administration (FDA) announced a consent decree entered by the US District Court for the Eastern District of New
DIETARY SUPPLEMENTS
FDA oversees destruction and recall of kratom products
Posted on
- On February 21, FDA issued a press release announcing the voluntary destruction and recall of a large volume of kratom-containing dietary supplements manufactured and distributed nationwide under the brand names
…
Continue Reading FDA oversees destruction and recall of kratom products
FDA Announces October Meeting on Pre-DSHEA List
Posted on
- Manufacturers or distributors of new dietary ingredients (NDIs) must submit a pre-market notification called a new dietary ingredient notification (NDIN) to FDA at least 75 days before marketing a dietary
…
Continue Reading FDA Announces October Meeting on Pre-DSHEA List
FDA Launches “Organ Chip” Project to Support Food and Dietary Supplement Safety Research
Posted on
- “Organs-on-Chips” technology has been the focus of a public-private collaboration between FDA, the federal Defense Advanced Research Projects Agency (DARPA) and the National Institutes of Health (NIH). “Organs-on-Chips” essentially involves
FSMA, Nutrition Panel Changes among Burdensome Federal Regulations, Industry Tells DOC
Posted on
- Members of the food and dietary supplement industries were among those who responded to a March 9, 2017 request from the U.S. Department of Commerce (DOC) for input on the
Supplement Spotlight: FDA Revised NDI Draft Guidance Does Not Alleviate Industry’s Concerns
Posted on
As previously reported on this blog, FDA issued a revised Draft Guidance titled, “Dietary Supplements: New Dietary Ingredient [NDI] Notifications and Related Issues,” in August 2016. The Agency received…
Continue Reading Supplement Spotlight: FDA Revised NDI Draft Guidance Does Not Alleviate Industry’s Concerns
Extension to Vinpocetine Comment Period Requested
Posted on
The Natural Products Association has asked FDA to extend the comment period deadline concerning the regulatory status of vinpocetine until September 6, 2017.
- Vinpocetine is a semisynthetic derivative of the
…
Continue Reading Extension to Vinpocetine Comment Period Requested
FDA Requests Comments on Regulatory Status of Vinpocetine
Posted on
FDA has requested comments on its “tentative conclusion” that vinpocetine is not eligible for use as a dietary ingredient.
- Vinpocetine is a semisynthetic derivative of the vinca alkaloid vincamine, an
…
Continue Reading FDA Requests Comments on Regulatory Status of Vinpocetine
Supplement Spotlight: FDA Revises NDI Draft Guidance
Posted on
- The Dietary Supplement Health and Education Act (DSHEA) requires the manufacturer or distributor of a
…
Continue Reading Supplement Spotlight: FDA Revises NDI Draft Guidance
Supplement Registry Update
Posted on
Leading dietary supplement trade association makes strides in developing product registry.
- As previously covered on this blog, a leading dietary supplement trade association — the Council for Responsible Nutrition